Gilead Sciences Inc. (NASDAQ:GILD) had its target price increased by stock analysts at Royal Bank Of Canada from $95.00 to $105.00 in a research report issued to clients and investors on Monday. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 34.56% from the stock’s current price.
A number of other equities research analysts have also commented on the stock. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $108.00 price objective on shares of Gilead Sciences in a research note on Monday, August 15th. Jefferies Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $76.89 to $91.00 in a research note on Tuesday, September 6th. Morgan Stanley reaffirmed a “hold” rating and issued a $103.00 price objective on shares of Gilead Sciences in a research note on Wednesday, June 15th. Berenberg Bank started coverage on shares of Gilead Sciences in a research note on Thursday, September 22nd. They issued a “buy” rating on the stock. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Sunday, July 10th. Ten equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $104.63.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 78.03 on Monday. The firm has a market capitalization of $102.97 billion, a price-to-earnings ratio of 6.85 and a beta of 1.10. Gilead Sciences has a 52 week low of $76.67 and a 52 week high of $111.11. The firm has a 50-day moving average of $79.35 and a 200 day moving average of $85.39.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the Zacks’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The company had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. During the same period in the prior year, the firm posted $3.15 EPS. The company’s quarterly revenue was down 5.7% on a year-over-year basis. On average, equities analysts predict that Gilead Sciences will post $11.76 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Investors of record on Friday, September 16th were issued a dividend of $0.47 per share. The ex-dividend date was Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.41%. Gilead Sciences’s dividend payout ratio (DPR) is presently 16.56%.
In other news, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $80.50, for a total value of $8,050,000.00. Following the completion of the transaction, the insider now owns 4,119,727 shares in the company, valued at $331,638,023.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $81.84, for a total transaction of $409,200.00. Following the completion of the transaction, the executive vice president now owns 132,964 shares of the company’s stock, valued at approximately $10,881,773.76. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Bank of Montreal Can acquired a new position in Gilead Sciences during the second quarter valued at $427,750,000. Capital World Investors increased its position in Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock valued at $1,277,907,000 after buying an additional 3,380,000 shares during the last quarter. Investec Asset Management LTD acquired a new position in Gilead Sciences during the first quarter valued at $280,342,000. Parnassus Investments CA increased its position in Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock valued at $705,774,000 after buying an additional 2,640,284 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. acquired a new position in Gilead Sciences during the first quarter valued at $180,268,000. Hedge funds and other institutional investors own 77.94% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.